Floatz logo

HER3 Dendritic Cell Vaccine

Anatomic Stage IV Breast Cancer AJCC v8

Roswell Park Cancer InstitutePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

890 Active assets in the Anatomic Stage IV Breast Cancer AJCC v8 cohort.

Asset / SponsorPhaseRating
Lapatinib
University of New Mexico
Phase 3BBB
Darolutamide
Vandana Abramson
Phase 2BBB
Trastuzumab Duocarmazine
Byondis B.V.
Phase 3BB
Palbociclib
Hoffmann-La Roche
Phase 4BB
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
SWOG Cancer Research Network
Phase 4BB

View all 50 →

Same molecule, other indications

HER3 Dendritic Cell Vaccine is also rated in:

metastatic malignant neoplasm in the brainDormant
CCC
Indicative ·
53 / 100
View asset →
triple-negative breast carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →